# Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma

> **NCT01310868** · PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 59 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** 5-ALA
- **DRUG:** Gliadel wafers
- **RADIATION:** Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
- **DRUG:** Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
- **DRUG:** Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist

## Key facts

- **NCT ID:** NCT01310868
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2017-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01310868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01310868, "Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01310868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*